Form 8-K - Current report:
SEC Accession No. 0001213900-22-065540
Filing Date
2022-10-21
Accepted
2022-10-21 16:30:15
Documents
15
Period of Report
2022-10-21
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea167111-8k_abvcbio.htm   iXBRL 8-K 40712
2 LETTER FROM KCCW ACCOUNTANCY CORP. TO THE U.S. SECURITIES AND EXCHANGE COMMISSIO ea167111ex16-1_abvcbio.htm EX-16.1 3367
6 GRAPHIC ex16-1_001.jpg GRAPHIC 40104
7 GRAPHIC ex16-1_002.jpg GRAPHIC 44529
  Complete submission text file 0001213900-22-065540.txt   333384

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abvc-20221021.xsd EX-101.SCH 3215
4 XBRL LABEL FILE abvc-20221021_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE abvc-20221021_pre.xml EX-101.PRE 22351
9 EXTRACTED XBRL INSTANCE DOCUMENT ea167111-8k_abvcbio_htm.xml XML 3502
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 221324054
SIC: 2834 Pharmaceutical Preparations